Cure My Disease

Don't miss your cure!

 Log in / Sign up

New ultrasound technique could reveal hidden blood vessels in liver tumors

NCT ID NCT07707661

Diagnosis Sponsor: Eastern Hepatobiliary Surgery Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests a new ultrasound method called super-resolution ultrasound (SRUS) to see tiny blood vessels in liver tumors. Current scans show only larger vessels, but SRUS can detect vessels as small as 20 micrometers. Researchers will compare blood flow patterns in different types of liver tumors, including cancer and benign growths, to see if this helps tell them apart. The goal is to improve diagnosis and treatment planning without needing a biopsy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
super-resolution ultrasound imaging
What this could lead to
If successful, this imaging technique could help doctors tell benign from malignant liver tumors more accurately, potentially reducing the need for biopsies.
What could go wrong
This is an early-stage imaging study, not a treatment trial. The technique may not prove reliable enough for routine clinical use, and results may vary by tumor type.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 350 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Liver tumor patients treated in the outpatient and inpatient departments of the Third Affiliated Hospital of the Naval Medical University.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Any gender, 18 years or older; 2. People newly diagnosed with liver tumors, including: ① Hepatocellular carcinoma; ② Cholangiocarcinoma; ③ Liver metastases; ④ Liver hemangioma; ⑤ Focal nodular hyperplasia of the liver. 3. Need to have a contrast-enhanced ultrasound as part of routine care; 4. Willing to join this study and sign the informed consent after discussing it with the doctor. Exclusion Criteria: 1. During the data collection process, if the participant is unable to cooperate fully, preventing the collection from being completed; 2. If the skin in the collection area is broken or scabbed, or if there's too much ascites in the abdominal cavity interfering with sound signal penetration, making data collection impossible; 3. Previous puncture biopsy or other treatments for existing liver malignant tumors; 4. Patients with a history of allergy, allergic constitution, or severe intolerance to sulfur hexafluoride or other components of the ultrasound contrast agent; 5. Patients who refuse to participate in this study; 6. Any uncontrollable comorbidities that could limit the patient's adherence to the study requirements or affect their ability to sign the written informed consent; 7. Poor overall condition or inability to tolerate relevant examinations; 8. Participants whom the researcher deems unsuitable for inclusion in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cholangiocarcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma focal nodular hyperplasia hepatocellular carcinoma intrahepatic cholangiocarcinoma liver hemangioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Focal nodular hyperplasia Hepatic hemangioma Hepatocellular carcinoma (HCC) Intrahepatic cholangiocellular carcinoma Liver metastasis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.